Iconic Therapeutics Company

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells to selectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed.
Technology: Geroscience
Industry: Biopharma, Biotechnology, Therapeutics
Headquarters: South San Francisco, California, United States
Founded Date: 1-1
Employees Number: 11-50
Investors Number: 8
Total Funding: $4.8M
Estimated Revenue: Less than $1M
Last Funding Type: Seed

Visit Website
Register and Claim Ownership